Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 4/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GNRHR | P30968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884237 | 0.88 | ADORA3 (0.43) | PDE5AADORA3KCNH2 | |
| SCHEMBL2881140 | 0.88 | PDE5A (0.44) | ALDH1A1PDE5AADORA3KCNH2 | |
| SCHEMBL2885760 | 0.87 | PDE5A (0.43) | ALDH1A1PDE5AADORA3KCNH2 | |
| SCHEMBL2883638 | 0.87 | ADORA3 (0.44) | PDE5AADORA3KCNH2 | |
| SCHEMBL2878080 | 0.86 | PDE5A (0.45) | PDE5AADORA3KCNH2 | |
| SCHEMBL2883547 | 0.86 | PDE5A (0.47) | PDE5AADORA3KCNH2 | |
| SCHEMBL2880700 | 0.85 | PDE5A (0.44) | PDE5AADORA3KCNH2 | |
| SCHEMBL2883633 | 0.85 | PDE5A (0.43) | PDE5AADORA3KCNH2 | |
| SCHEMBL2878452 | 0.84 | PDE5A (0.44) | PDE5AADORA3KCNH2 | |
| SCHEMBL2878060 | 0.84 | PDE5A (0.43) | PDE5AADORA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | BAYER HEALTHCARE AG (DE) | 2010-01-07 | — | — | US | disclosed |
| EP-2013205-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | Bayer HealthCare AG (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007124854-A1 | HETEROCYCLIC SUBSTITUTED, ANELLATED PYRAZOLE DERIVATIVE AND ITS USES | BAYER HEALTHCARE AG (DE) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004235-A1 | Heterocyclic Substituted, Anellated Pyrazole Derivative and its uses | AADAC, CYP11B2, PC | GSK3B 3071/4885PDE1B 1355/4885ALDH1A1 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.